Genetic syndromic sensorineural hearing loss.

Pneumonia, or chronic lung disease requiring oxygen.

Immunosuppression as defined by WBC 100ml lesion).

Hepatic disease or altered liver function as defined by SGPT > 150 U/L, and or T.

Renal disease of altered renal function as defined by serum creatinine > 1.5 mg/dl at admission.

Recently treated infection less than 2 weeks before infusion.

(pertinent physician notes, speech language pathology notes, laboratory findings, test results and imaging studies-must be sent to the research team at least prior to the subject arriving at the study location for preliminary screening and eligibility assessment, preferably14 days before the scheduled hUBC treatment.).

Inability to obtain all pertinent medical records:

Ability of the child and caregiver to travel to Orlando, and stay for at least 4 days, and to return for all follow-up visits.

Age 6 weeks - 6 years old at time of infusion with less than 18 months of hearing loss at the time of cord blood infusion.

Enrollment in a parent/child intervention program.

Fitted for hearing aids no later than six months post detection of loss.

Normally shaped cochlea, as determined by MRI.Moderate to profound in degree (40-90 Decibels (dB) in at least one ear.Symmetrical or asymmetrical configuration.Unilateral or bilateral in configuration.Why Should I Register and Submit Results?.When transplanted into the cochlea of animals with hearing loss, auditory restoration has been documented to date only in deafferented animals.Īdvances have been more prominent in cases of auditory neuropathy, since partial improvement of auditory nerve conditions through cell-based therapy may increase the number of patients who can successfully receive cochlear implants.Īuditory neurons Cellular therapy Células ciliadas Células-tronco Hair cells Neurônios auditivos Stem cells Terapia celular.Ĭopyright © 2019 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Remarkably, these differentiated cells are able to interact with hair cells and auditory neurons of cochlear explants through formation of new synapses. The research was conducted independently by three researchers.ĭifferentiation of stem cells into hair cells and auditory neurons has a high success rate, reaching up to 82% for the first and 100% for the latter. Additionally, the main terms were combined with the following secondary terms: 'mesenchymal', 'iPS', 'inner ear', 'auditory'. Search strategy included the following main terms: 'stem cells', 'hair cells' and 'auditory neurons'. Research included the databases PubMed/MEDLINE, Web of Science, Science Direct and SciELO, as well as gray literature. This article aims to review the current literature about the main types of stem cells with potential for application in cell therapy for sensorineural hearing loss, the most relevant experiments already performed in animals, as well as the advances that have been recently made in the field. Regenerative therapies using stem cells represent a promising alternative. However, there is no treatment that re-establishes auditory function. Hence, damage to these cell types is permanent and leads to hearing loss.

Mammalian hair cells and auditory neurons do not show regenerative capacity.

Stem cell treatment for hearing loss